Evaluation of the teratogenic potential of the dopamine agonist bromocriptine in rats.
Single subcutaneous injections of bromocryptine (BCR; 2 mg/kg) to rats on days 5, 7 or 10 of gestation caused a lowering of the serum prolactin (PRL) concentration and, on days up to and including day 8 of gestation, abortion of entire litters. Coincident with the end of the PRL-dependent phase of gestation (approximately day 9), BCR was no longer abortifacient, allowing higher doses of the drug to be administered from this time without the risk of abortion. Treatment at 50 or 100 mg/kg from day 10 to 16 of pregnancy, despite affecting the dams (increased water consumption), had no adverse effects on pregnancy or fetal development.
Narburgh
L J
LJ
Smith Kline & French Research Ltd., Welwyn, Hertfordshire, U.K.
Turner
J
J
Freeman
S J
SJ
D000014:Abnormalities, Drug-Induced; D000818:Animals; D001971:Bromocriptine / Q000633:toxicity*; D003338:Corpus Luteum / Q000187:drug effects; D018492:Dopamine Antagonists; D004305:Dose-Response Relationship, Drug; D004326:Drinking / Q000187:drug effects; D005314:Embryonic and Fetal Development / Q000187:drug effects; D005260:Female; D005865:Gestational Age; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000097:blood / Q000187:drug effects*; D011388:Prolactin / Q000097:blood; D051381:Rats; D011919:Rats, Inbred Strains
D018492:Dopamine Antagonists; D001971:Bromocriptine; D011388:Prolactin